VPVincent E. Provasek

Vincent E. Provasek

*This is an algorithmically generated author record based on publicly available information.

Vincent E. Provasek has a total of 57 co-authors. Here are the top co-authors by number of shared publications:

  • Muralidhar L. Hegde

    Division of DNA Repair Research, Center for Neuroregeneration, Department of Neurosurgery, Houston Methodist Research Institute, Houston, USA

    5 shared publications
  • Joy Mitra

    Division of DNA Repair Research within the Center for Neuroregeneration, Department of Neurosurgery, Houston Methodist Research Institute, Houston, USA

    3 shared publications
  • Manohar Kodavati

    Division of DNA Repair Research within the Center for Neuroregeneration, Department of Neurosurgery, Houston Methodist Research Institute, Houston, USA

    3 shared publications
  • Brandon Kim

    Department of Neuroscience, Rice University, Houston, USA

    2 shared publications
  • Abigail Abigail Giese

    Department of Cardiovascular Sciences, Houston Methodist Research Institute

    1 shared publication
  • Akshay R. Prabhakar

    Department of Otolaryngology – Head and Neck Surgery Houston Methodist Hospital Houston Texas USA

    1 shared publication

Latest Publications

  • From head shape to diagnosis: Craniosynostosis for the pediatric neurologist

    by Joseph D. Quick, Vincent E. Provasek, Lauren E. Powell, Ruth J. Barta, Robert F. Dempsey


  • Open Access

    Outcomes of Mobile Health Use in Sinonasal Surgery: A Retrospective Cohort Study (Preprint)

    by Heli Majeethia, Akshay R. Prabhakar, Justina R. Varghese, Najm S. Khan, Roshan Dongre, Vincent Provasek, Faizaan I. Khan, Zain Mehdi, Omar G. Ahmed, Masayoshi Takashima

    Background: Mobile health (mHealth) technologies are increasingly integrated into perioperative care to enhance patient engagement and communication. Prior studies in surgical and medical specialties suggest that mHealth platforms may be associated with reductions in hospital stay and readmissions; however, evidence supporting their impact in otolaryngology, particularly in sinonasal surgery, remains limited. Objective: The aim of this study was to evaluate the association between perioperative enrollment in CareSense, a patient-facing mHealth platform, and postoperative health care utilization outcomes, including hospital readmissions, emergency department (ED) visits, and length of stay (LOS), among adults undergoing sinonasal surgery. Methods: This is a retrospective cohort study performed at a single tertiary care academic medical center between May 2021 and January 2024. All adult patients (≥18 years) who underwent sinonasal surgery with two fellowship-trained rhinologists during the study period were included. CareSense was offered to all patients at the time of surgical scheduling, and enrollment was voluntary. Patients were categorized into CareSense participants and nonparticipants. Primary outcomes were all-cause hospital readmissions and ED visits within 30, 60, and 90 days following surgery. Secondary outcomes included the length of hospital stay among readmitted patients. Clinical, demographic, and outcome data were obtained through retrospective electronic health record review. Univariate analyses compared outcomes between groups, and multivariable logistic regression using generalized estimating equations was performed to estimate the association between CareSense participation and outcomes while adjusting for age, sex, hypertension, and diabetes. Results: A total of 1135 patients were included, of whom 340 (30%) enrolled in CareSense and 795 (70%) did not. Compared with nonparticipants, CareSense participants had lower adjusted odds ratio (OR) for readmission for any cause at 30 days (OR 0.24, 95% CI 0.08‐0.75; P =.007), 60 days (OR 0.40, 95% CI 0.19‐0.83; P =.01), and 90 days (OR 0.54, 95% CI 0.29‐0.99; P =.04). Among patients who were readmitted, mean LOS was shorter in the CareSense group than in the nonparticipating group (0.17 vs 1.68 d; P <.001). The majority of readmissions in both cohorts were unrelated to complications of the index sinonasal procedure. Conclusions: This study demonstrates the benefit of CareSense in lowering postoperative readmission rates and LOS for sinonasal surgery patients, illustrating the role of medical health technology in improving patient care and quality outcomes. Perioperative enrollment in a patient-facing mHealth platform was associated with lower postoperative health care utilization and shorter hospital length of stay following sinonasal surgery. Given the voluntary nature of enrollment and the observational design, these findings should be interpreted as observation findings and hypothesis-generating for prospective studies to more definitively assess the causal impact of mHealth interventions and to identify which components of digital perioperative care most effectively improve outcomes in otolaryngologic surgery.

  • Open Access

    Chronic subdural hematoma: What precisely are we treating?

    by Yang Qiao, Sáfa Alkarawi, Vincent E Provasek, Yi Jonathan Zhang, Samuel Tsappidi, Ferdinand Hui

    Subdural hematoma (SDH) refers to the collection of blood between the dura matter and the arachnoid membrane. Advancements in imaging technology have enabled the categorization of SDH based on specific imaging characteristics, causative factors, and the onset of symptoms. Given that the prognosis of SDHs varies significantly and is contingent upon the size and chronicity of the hemorrhage, a comprehensive understanding of its subtypes may carry crucial treatment implications. For example, an acute SDH classically results from severe traumatic brain injury and appears as a homogenous, crescent-shaped hyperdense extra-axial collection. If not treated, over the course of 1–3 weeks, this hematoma will evolve into a sub-acute phenotype as a consequence of subdural effusion and demonstrate mixed-density hemorrhage on imaging. Chronic SDH (cSDH) becomes the end result of an untreated SDH, with neo-membranization and neo-angiogenesis from branches of the middle meningeal artery driving a mass-like growth pattern. This review article aims to elucidate the complex anatomical features of the end-stage cSDH, with a particular focus on reconceptualization of this entity based on its mass-like growth patterns, and how this is driving a shift towards endovascular treatment.


  • Open Access

    Polycystin-1 loss of function increases susceptibility to atrial fibrillation through impaired DNA damage response

    by Troy Hendrickson, Abigail Abigail Giese, Matthew Fiedler, William Perez, Ernesto Reyes-Sanchez, Monserrat Reyes-Lozano, Sufen Wang, Leslye Venegas-Zamora, Vincent Provasek, Aschraf El-Essawi, et al.

    Background The increasing prevalence of atrial fibrillation (AF) and chronic kidney diseases highlights the need for a deeper comprehension of the molecular mechanisms linking them. Mutations in PKD1, the gene encoding Polycystin-1 (PKD1 or PC1), account for 85% of autosomal dominant polycystic kidney disease (ADPKD) cases. This disease often includes cardiac complications such as AF. In cardiomyocytes, PC1 deletion reduces hypertrophic response to pressure overload but promotes baseline ventricular dysfunction, while deletion in fibroblasts ameliorates post-myocardial infarction fibrosis. Despite its known cardiac impact, the role of PC1 in atrial cardiomyocytes and arrhythmias is less understood. Here, we sought to investigate the role of PC1 in AF. Methods We used intracardiac programmed stimulation and optical mapping to evaluate AF inducibility in two mouse models, Pkd1 R3277C, which recapitulates human ADPKD progression, and cardiomyocyte-specific Pkd1 deletion, and their respective controls. Isolated adult mouse atrial cardiomyocytes, human iPSC-derived atrial cardiomyocytes (hiPSC-aCM), and HL-1 cells served as in vitro cellular models. Molecular mechanisms were evaluated using optical mapping and molecular and biochemical approaches. Results Loss-of-function PC1 mutations significantly increased AF susceptibility in vivo and facilitated local reentry in ex vivo left atrial appendages. Comprehensive in vitro experiments supported a direct effect of PC1 in atrial cardiomyocytes. PC1-deficient monolayers exhibited increased arrhythmic events, escalating into reentrant spiral waves post-tachypacing. Transcriptomics analysis revealed PC1-dependent regulation of DNA repair, with PC1 deficiency leading to increased DNA damage under stress. PARP1 inhibitors or nicotinamide riboside, which counteract DNA damage-related metabolic consequences, reduced in vitro arrhythmias PC1-deficient monolayers. Overexpression of the C-terminus of PC1 had the opposite effects in DNA repair genes, suggesting its regulatory effects in atrial cardiomyocytes through retinoblastoma/E2F. Analyses of human atrial tissue from non-ADPKD AF patients showed reduced levels of mature PC1, suggesting a broader relevance of impaired PC1 in AF. Conclusions Impaired PC1 increases in vivo AF inducibility under programmed electrical stimulation and promotes in vitro arrhythmias in hiPSC-aCM and HL-1 cells. Our findings indicate that PC1 protects against DNA damage to reduce AF susceptibility.

  • Open Access

    TDP43 interacts with MLH1 and MSH6 proteins in a DNA damage-inducible manner

    by Vincent E. Provasek, Manohar Kodavati, Brandon Kim, Joy Mitra, Muralidhar L. Hegde

    Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that affects the motor neuron. One aspect of the neuropathology involved in ALS includes increased genomic damage and impaired DNA repair capability. The TAR-DNA binding protein 43 (TDP43) has been associated with both sporadic and familial forms of ALS, and is typically observed as cytosolic mislocalization of protein aggregates, termed TDP43 proteinopathy. TDP43 is a ubiquitous RNA/DNA binding protein with functional implications in a wide range of disease processes, including the repair of DNA double-strand breaks (DSBs). While TDP43 is widely known to regulate RNA metabolism, our lab has reported it also functions directly at the protein level to facilitate DNA repair. Here, we show that the TDP43 protein interacts with DNA mismatch repair (MMR) proteins MLH1 and MSH6 in a DNA damage-inducible manner. We utilized differentiated SH-SY5Y neuronal cultures to identify this inducible relationship using complementary approaches of proximity ligation assay (PLA) and co-immunoprecipitation (CoIP) assay. We observed that signals of TDP43 interaction with MLH1 and MSH6 increased significantly following a 2 h treatment of 10 μM methylmethanesulfonate (MMS), a DNA alkylating agent used to induce MMR repair. Likewise, we observed this effect was abolished in cell lines treated with siRNA directed against TDP43. Finally, we demonstrated these protein interactions were significantly increased in lumbar spinal cord samples of ALS-affected patients compared to age-matched controls. These results will inform our future studies to understand the mechanisms and consequences of this TDP43-MMR interaction in the context of ALS-affected neurons.


  • Open Access

    TDP43 Interacts with MLH1 and MSH6 Proteins in A DNA Damage-Inducible Manner

    by Vincent E. Provasek, Manohar Kodavati, Brandon Kim, Joy Mitra, Muralidhar L. Hegde

    Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that affects the motor neuron. One aspect of the neuropathology involved in ALS includes increased genomic damage and impaired DNA repair capability. The TAR-DNA binding protein 43 (TDP43) has been associated with both sporadic and familial forms of ALS, and is typically observed as cytosolic mislocalization of protein aggregates, termed TDP43 proteinopathy. TDP43 is a ubiquitous RNA/DNA binding protein with functional implications in a wide range of disease processes, including the repair of DNA double strand breaks (DSBs). While TDP43 is widely known to regulate RNA metabolism, our lab has reported it also functions directly at the protein level to facilitate DNA repair. Here, we show that TDP43 protein interacts with DNA mismatch repair (MMR) proteins MLH1 and MSH6 in a DNA damage-inducible manner. We utilized differentiated SH-SY5Y neuronal cultures to identify this inducible relationship using complimentary approaches of proximity ligation assay (PLA) and co-immunoprecipitation (CoIP) assay. We observed that signals of TDP43 interaction with MLH1 and MSH6 increased significantly following a 2 hr treatment of 10μM methylmethanesulfonate (MMS), a DNA alkylating agent used to induce MMR repair. Likewise, we observed this effect was abolished in cell lines treated with siRNA directed against TDP43. Finally, we demonstrated these protein interactions were significantly increased in lumbar spinal cord samples of ALS-affected patients compared to age-matched controls. These results will inform our future studies to understand the mechanisms and consequences of this TDP43-MMR interaction in the context of ALS affected neurons.

  • Open Access

    RNA/DNA Binding Protein TDP43 Regulates DNA Mismatch Repair Genes with Implications for Genome Stability

    by Vincent E. Provasek, Albino Bacolla, Suganya Rangaswamy, Manohar Kodavati, Joy Mitra, Issa O. Yusuf, Vikas H. Malojirao, Velmarini Vasquez, Gavin W. Britz, Guo-Min Li, et al.

    TDP43 is an RNA/DNA binding protein increasingly recognized for its role in neurodegenerative conditions, including amyotrophic lateral sclerosis and frontotemporal dementia (FTD). As characterized by its aberrant nuclear export and cytoplasmic aggregation, TDP43 proteinopathy is a hallmark feature in over 95% of ALS/FTD cases, leading to the formation of detrimental cytosolic aggregates and a reduction in nuclear functionality within neurons. Building on our prior work linking TDP43 proteinopathy to the accumulation of DNA double-strand breaks (DSBs) in neurons, the present investigation uncovers a novel regulatory relationship between TDP43 and DNA mismatch repair (MMR) gene expressions. Here, we show that TDP43 depletion or overexpression directly affects the expression of key MMR genes. Alterations include MLH1, MSH2, MSH3, MSH6, and PMS2 levels across various primary cell lines, independent of their proliferative status. Our results specifically establish that TDP43 selectively influences the expression of MLH1 and MSH6 by influencing their alternative transcript splicing patterns and stability. We furthermore find aberrant MMR gene expression is linked to TDP43 proteinopathy in two distinct ALS mouse models and post-mortem brain and spinal cord tissues of ALS patients. Notably, MMR depletion resulted in the partial rescue of TDP43 proteinopathy-induced DNA damage and signaling. Moreover, bioinformatics analysis of the TCGA cancer database reveals significant associations between TDP43 expression, MMR gene expression, and mutational burden across multiple cancers. Collectively, our findings implicate TDP43 as a critical regulator of the MMR pathway and unveil its broad impact on the etiology of both neurodegenerative and neoplastic pathologies.


  • Open Access

    lncRNA Sequencing Reveals Neurodegeneration-Associated FUS Mutations Alter Transcriptional Landscape of iPS Cells That Persists in Motor Neurons

    by Vincent E. Provasek, Manohar Kodavati, Wenting Guo, Haibo Wang, Istvan Boldogh, Ludo Van Den Bosch, Gavin Britz, Muralidhar L. Hegde

    Fused-in sarcoma (FUS) gene mutations have been implicated in amyotrophic lateral sclerosis (ALS). This study aimed to investigate the impact of FUS mutations (R521H and P525L) on the transcriptome of induced pluripotent stem cells (iPSCs) and iPSC-derived motor neurons (iMNs). Using RNA sequencing (RNA Seq), we characterized differentially expressed genes (DEGs) and differentially expressed lncRNAs (DELs) and subsequently predicted lncRNA–mRNA target pairs (TAR pairs). Our results show that FUS mutations significantly altered the expression profiles of mRNAs and lncRNAs in iPSCs. Using this large dataset, we identified and verified six key differentially regulated TAR pairs in iPSCs that were also altered in iMNs. These target transcripts included: GPR149, NR4A, LMO3, SLC15A4, ZNF404, and CRACD. These findings indicated that selected mutant FUS-induced transcriptional alterations persist from iPSCs into differentiated iMNs. Functional enrichment analyses of DEGs indicated pathways associated with neuronal development and carcinogenesis as likely altered by these FUS mutations. Furthermore, ingenuity pathway analysis (IPA) and GO network analysis of lncRNA-targeted mRNAs indicated associations between RNA metabolism, lncRNA regulation, and DNA damage repair. Our findings provide insights into potential molecular mechanisms underlying the pathophysiology of ALS-associated FUS mutations and suggest potential therapeutic targets for the treatment of ALS.


  • Open Access

    DNA Double-Strand Breaks as Pathogenic Lesions in Neurological Disorders

    by Vincent E. Provasek, Joy Mitra, Vikas H. Malojirao, Muralidhar L. Hegde

    The damage and repair of DNA is a continuous process required to maintain genomic integrity. DNA double-strand breaks (DSBs) are the most lethal type of DNA damage and require timely repair by dedicated machinery. DSB repair is uniquely important to nondividing, post-mitotic cells of the central nervous system (CNS). These long-lived cells must rely on the intact genome for a lifetime while maintaining high metabolic activity. When these mechanisms fail, the loss of certain neuronal populations upset delicate neural networks required for higher cognition and disrupt vital motor functions. Mammalian cells engage with several different strategies to recognize and repair chromosomal DSBs based on the cellular context and cell cycle phase, including homologous recombination (HR)/homology-directed repair (HDR), microhomology-mediated end-joining (MMEJ), and the classic non-homologous end-joining (NHEJ). In addition to these repair pathways, a growing body of evidence has emphasized the importance of DNA damage response (DDR) signaling, and the involvement of heterogeneous nuclear ribonucleoprotein (hnRNP) family proteins in the repair of neuronal DSBs, many of which are linked to age-associated neurological disorders. In this review, we describe contemporary research characterizing the mechanistic roles of these non-canonical proteins in neuronal DSB repair, as well as their contributions to the etiopathogenesis of selected common neurological diseases.